The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Srcmediated tumor growth remain unclear. Here we examined the involvement of microRNAs in the c-Src-mediated tumor growth. Microarray profiling revealed that c-Src activation downregulates a limited set of microRNAs, including miR-99a, which targets oncogenic mammalian target of rapamycin (mTOR) and fibroblast growth factor receptor 3 (FGFR3). Re-expression of miR-99a suppressed tumor growth of c-Src-transformed cells, and this effect was restored by the overexpression of mTOR. The downregulation of miR-99a was also observed in epidermal growth factor-and Ras-transformed cells, and it was suppressed by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Furthermore, miR-99a downregulation is associated with mTOR/FGFR3 upregulation in various human lung cancer cells/tissues. The tumorigenicity of these cells was suppressed by the introduction of miR-99a. These findings suggest that the miR-99a-mTOR/FGFR3 pathway is crucial for controlling tumor growth in a wide range of human cancers that harbor upregulation of the Src-related oncogenic pathways.
Introduction
The tyrosine kinase c-Src is a pivotal component of multiple signaling pathways that regulate cell proliferation, survival, adhesion and migration, which are processes tightly associated with tumor progression (Brown and Cooper, 1996; Ingley, 2008) . c-Src is frequently overexpressed and activated in a wide variety of human cancers, suggesting a role in tumor progression (Frame, 2002; Ishizawar and Parsons, 2004; Yeatman, 2004) . In normal cells, the kinase activity of c-Src is rigorously controlled by the C-terminal Src kinase (Csk) Okada et al., 1991) ; therefore, the oncogenic potential of c-Src is suppressed even when c-Src is abundantly expressed. In some cancer cells, however, c-Src function is upregulated despite the fact that the c-src gene is rarely mutated (Irby et al., 1999; Irby and Yeatman, 2000) . Thus, it is considered that disruption of the strict regulation of c-Src may trigger cancer progression, although the underlying mechanisms remain unclear. Once activated, c-Src acts as a common upstream regulator of various oncogenic pathways, including the Ras/MAPK pathway, STAT and phosphoinositide 3-kinase (PI3K) pathways (Ingley, 2008) , to induce the phenotypic changes characteristic of cell transformation. Mounting evidence shows the importance of c-Src in cancer progression, but the complexity of c-Src function has hampered the elucidation of the critical c-Src pathways involved in directing tumor growth.
MicroRNAs (miRNAs) are a class of small RNA molecules approximately 22 nucleotides long that regulate gene expression by blocking mRNA translation and/or mediating mRNA degradation (Ambros, 2004; Bartel, 2004 Bartel, , 2009 Ventura and Jacks, 2009) . More than 600 different miRNAs have so far been identified in human beings, and they have been shown to control diverse cellular functions, including cell proliferation and differentiation (He and Hannon, 2004; Bartel, 2009) . Each miRNA is predicted to target hundreds of genes, and each transcript may interact with multiple miRNAs (Bartel, 2009 ). This interplay between miRNA and transcripts underscores the potential role of miRNAs as key regulators of complex signaling networks. In recent years, numerous studies have shown aberrant expression of miRNAs in human cancers (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006) . In addition, some miRNAs are located in unstable genomic regions and are often downregulated in tumors (Calin and Croce, 2006) . These lines of evidence strongly suggest that a group of miRNAs functions as oncogenes or tumor suppressors (Shenouda and Alahari, 2009 ).
The PI3K pathway is a key signal-transduction system that links multiple receptors and oncogenic molecules to diverse cellular functions and is inappropriately activated in many human cancers (Engelman, 2009; Liu et al., 2009) . Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is a major downstream effector of the PI3K pathway and plays a crucial part in the regulation of cell growth by monitoring nutrient availability, cellular energy levels, oxygen levels and mitogenic signals (Wullschleger et al., 2006) . The mTOR signaling pathway has also been implicated in tumorigenesis (Petroulakis et al., 2006; Guertin and Sabatini, 2007; Nagaraja et al., 2010) . Indeed, rapamycin, a selective mTORC1 inhibitor, has antineoplastic properties, and its analogues have been developed as anticancer drugs. Major downstream targets of mTORC1 are ribosomal protein S6 kinase 1 (S6K1, also known as p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1, both of which play crucial roles in the regulation of protein synthesis (Hay and Sonenberg, 2004) . Therefore, activation of the mTOR pathway provides tumor cells with a growth advantage by promoting protein synthesis (Sabatini, 2006; Menon and Manning, 2008) . In human cancers, the PI3K pathway is activated by either upregulation of receptor tyrosine kinases or somatic mutations in specific components of the pathway (Liu et al., 2009) . Fibroblast growth factor receptor 3 (FGFR3) is one of the receptors that promote cell survival by stimulating PI3K-AKT signaling (Ong et al., 2001) . Overexpression and/or mutation of FGFR3 are frequently observed in myeloma, ovarian and bladder cancers, suggesting that this molecule plays a role in tumorigenesis (van Rhijn et al., 2001; Eswarakumar et al., 2005) .
To address the molecular mechanisms underlying c-Src-mediated cell transformation, we previously developed a model system using Csk-deficient fibroblasts (Csk À/À cells) that can be transformed by wild-type c-Src (Oneyama et al., 2008) . In this system, the activation of relatively small numbers of molecules is sufficient for induction of cell transformation and tumorigenesis (Oneyama et al., 2008) . These findings suggest that this system could be useful in the identification of critical pathways leading to c-Src transformation. In this study, this experimental system was applied for the analysis of potential contribution of miRNAs to c-Src-mediated tumor growth. Expression profiling of miRNAs in Csk À/À cells revealed that a limited set of miRNAs are differentially regulated by c-Src transformation. In particular, we focused our analysis on miR-99a based on its significant downregulation by c-Src transformation. We show that miR-99a is downregulated in various human cancers and targets mTOR and FGFR3 genes that are tightly associated with human cancers. Functional analysis of miR-99a in c-Src/Ras-transformed cells and various human cancer cells/tissues suggests that miR-99a is downregulated by the activation of Srcrelated oncogenic pathways and functions as a suppressor of tumor growth by controlling the expression of mTOR/FGFR3.
Results
miRNA expression profiling in c-Src-transformed cells Previously, we developed an experimental system using Csk
À/À cells to analyze the molecular mechanisms underlying c-Src-mediated transformation (Oneyama et al., 2008) . Despite the activation of endogenous c-Src, the cells do not transform owing to the substantial degradation of activated c-Src by the ubiquitin-proteasome system (Hakak and Martin, 1999) . However, exogenous expression of c-Src, at levels over twice the endogenous level, efficiently induced cell transformation (Oneyama et al., 2008) . Using these cells, we compared the expression profiles of miRNAs between nontransformed cells (Csk À/À cells and those expressing Csk or c-Src plus Csk) and c-Src-transformed cells (Csk À/À cells expressing c-Src) through miRNA microarray analysis. Pair-wise significance analysis of the microarray data (see Supplementary information) indicated that seven miRNA genes were downregulated ( Figure 1a ) and six miRNA genes were significantly upregulated in c-Src-transformed cells.
Quantitative real-time PCR (qRT-PCR) analyses confirmed the downregulation of the seven miRNAs in c-Src-transformed cells (Figure 1b ). These miRNAs were categorized into three clusters based on their chromosomal locations of mouse: miR-23b and -27b are located on chromosome (Chr.) 13, miR-322, -450a, -503 and -542 are on Chr. X, and miR-99a is on Chr. 16. These findings suggest a potential role of these miRNAs in regulating transformation via the c-Src-mediated pathway.
miR-99a as a suppressor of c-Src-induced tumor growth Recent studies have reported that miR-99a is transcribed from the commonly deleted region at 21q21 in human lung cancers (Nagayama et al., 2007; Yamada et al., 2008) and that miR-99a is downregulated in ovarian carcinoma (Nam et al., 2008) , squamous cell carcinoma of the tongue (Wong et al., 2008) , bladder cancer (Catto et al., 2009) , squamous cell lung carcinoma (Gao et al., 2010) and childhood adrenocortical tumors (Doghman et al., 2010) . These findings indicate that miR-99a is widely downregulated in human cancers, suggesting a potential role for miR-99a as a tumor suppressor. Thus, we further concentrated on miR-99a and tested if miR-99a is involved in regulating c-Src-induced transformation and tumor growth. Overexpression of miR-99a did not induce changes in cell morphology or cytoskeletal organization of c-Srctransformed cells (Figure 2a ). In addition, miR-99a expression did not affect c-Src-induced tyrosine phosphorylation of cellular proteins or the activity of c-Src (pY416) or Erk (p-Erk), although it slightly inhibited AKT activity (Figure 2b ). An in vitro proliferation assay showed that miR-99a expression only weakly suppressed anchorage-dependent growth of these cells (Supplementary Figure 1 ). However, a colony formation assay in soft agar revealed that miR-99a expression dramatically suppressed anchorage-independent growth of c-Srctransformed cells in a dose-dependent manner miR-99a controls c-Src-mediated tumor growth C Oneyama et al ( Figure 2c ). Tumorigenesis of c-Src-transformed cells in nude mice was also remarkably suppressed by the expression of miR-99a (Figure 2d ). These results suggest that miR-99a functions as a suppressor of tumor growth induced by the activation of c-Src in these cells.
miR-99a targets mTOR and FGFR3
To elucidate the function of miR-99a, we performed a bioinformatic search (Targetscan and Pictar) for putative targets of miR-99a. Interestingly, miR-99a was found to have relatively few potential targets miR-322, -27b, -23b, -99a, -450a-5p, -542-3p and -503) that downregulated twofold in c-Src-transformed cells were subjected to hierarchical clustering (right side). In each panel, the selected miRNAs are shown in the lines and four pairs of duplicates in the columns. The color bar indicates the fold-change (log 2). Red denotes upregulated and green denotes downregulated. (b) The expression of seven miRNAs downregulated was analyzed using qRT-PCR. Relative values±s.d. were obtained from three independent assays. miR-99a controls c-Src-mediated tumor growth C Oneyama et al (around 40), which included several cell signaling molecules. Among the candidates, the 3 0 -untranslated regions of mTOR and FGFR3 contained regions that matched the seed sequences of miR-99a ( Figure 3a) . A luciferase reporter assay in c-Src-transformed cells showed that miR-99a specifically targeted the miR-99a binding sequences in mTOR and FGFR3 mRNAs ( Figure 3b ). Conversely, introduction of anti-miR-99a enhanced the expression of luciferase reporter of both constructs in non-transformed Csk À/À cells, which express miR-99a at higher levels ( Figure 3c ). These results indicate that miR-99a can directly target mTOR and FGFR3 mRNA to regulate their expression.
We then examined the impact of miR-99a expression on the endogenous mTOR and FGFR3 proteins. Western blot analysis showed that both proteins were upregulated by c-Src transformation ( Figure 3d , lanes 1 vs 3), whereas they were significantly downregulated by Although the extent of these upregulations was not so remarkable, it was sufficient to restore a significant colony-forming activity in these cells (Figure 4b ). We also observed that inhibition of mTOR activity with the selective inhibitor rapamycin effectively suppressed tumor growth of c-Src-transformed cells as well as A549 cells that have c-Src upregulation (Supplementary Figure 2) . These findings suggest that the mTOR activity is correlated with the ability of c-Src to induce tumor growth.
To further verify the significance of upregulation of mTOR protein levels in tumor growth, we differentially overexpressed mTOR protein in non-transformed Csk À/À cells, in which c-Src is activated insufficiently for cell transformation (Oneyama et al., 2008) . The expression of mTOR protein dose-dependently enhanced p70S6K activity and the colony-forming activity of these cells, and the expression of mTOR at nearly twice the normal level was sufficient to induce colony formation (Figure 4c ). More interestingly, when mTOR was upregulated by inactivating miR-99a using antimiR-99a, non-transformed Csk À/À cells gained the ability to form colonies in a manner dependent on the concentrations of anti-miR-99a (Figure 4d and Supplementary Figure 3 ). These results suggest that mTOR can dose-dependently control the potential for tumor growth, within a range regulatable by miR-99a. However, the colony-forming activity of mTOR-overexpressing cells (Figure 4c miR-99a controls c-Src-mediated tumor growth C Oneyama et al and Figure 2c ). This indicates that mTOR is required, but insufficient for inducing full transformation, because critical pathways, such as the MAPK pathway, which are required for cell proliferation, were not activated by the expression of mTOR.
On the other hand, the transfection of c-Src-transformed cells with the FGFR3 ORF induced a substantial overexpression of FGFR3 protein even in miR99a-treated cells (Figure 4e ), but it only moderately rescued c-Src-mediated tumor growth (Figure 4f ). However, it should be noted that mTOR was also downregulated by miR-99a even in FGFR3-overexpressing cells. Thus, it seems probable that the recovery of tumor growth by FGFR3 expression may be cancelled by the downregulation of mTOR. In contrast, the selective FGFR3 inhibitor PD173074 (Trudel et al., 2004) was able to dose-dependently suppress colonyforming activity of c-Src-transformed cells and A549 cells (Supplementary Figure 4) . Therefore, it is likely that upregulation of FGFR3 can also contribute to c-Src-mediated tumor growth by acting upstream of mTOR.
miR-99a is downregulated by Src-related oncogenic pathways To follow the signaling pathway leading to the downregulation of miR-99a, we first tested the contribution of epidermal growth factor receptor (EGFR) signaling involving c-Src activation. When murine embryonic fibroblasts (MEFs) were stimulated with EGF, the kinase activity of c-Src was increased by auto-phosphorylation at Y418 (Figure 5a , left panels), and the cells showed morphological transformation (data not shown). In these EGF-transformed cells, the expression of miR-99a was appreciably downregulated (Figure 5b) . Conversely, the expression of mTOR and FGFR3 was upregulated by EGF stimulation (Figure 5a , right panels). These results indicate that the expression of miR-99a can also be regulated downstream of EGFR signaling. To further identify the pathway downstream of this EGFR signaling, we examined the effect of an MAPK/ERK kinase (MEK) inhibitor (U0126) or a PI3K inhibitor (LY294002) on EGF-induced downregulation of miR-99a. The expression of miR-99a was significantly restored by treatment with U0126, but not by LY294002 (Figure 5c ), suggesting that miR-99a expression is mainly regulated via the MEK/ERK pathway. These findings led to the question as to whether the downregulation of miR-99a can be induced by other oncogenes such as v-Src, H-RasV12 and K-RasG12, all of which can activate the MEK/ERK pathway. As expected, transformation by these oncogenes induced a significant downregulation of miR-99a to a level similar to that observed in c-Src-transformed cells (Figures 5d  and 1b) , and inversely caused upregulation of mTOR and FGFR3 proteins (Figure 5e ). The ectopic expression of miR-99a in these cells downregulated mTOR and FGFR3 proteins (Figure 5e ) and significantly suppressed their colony-forming activities (Figure 5f ). These findings suggest that the expression of miR-99a can be downregulated via the Ras-MEK/ERK pathway downstream of activated EGFR/Src.
miR-99a in human cancer cells
To examine if the miR-99a-mTOR/FGFR3 axis is indeed functional in human cancers, we determined the expression levels of miR-99a and mTOR/FGFR3 in several human lung cancer cell lines. Western blot analysis showed a significant upregulation of mTOR and FGFR3 in all of the lung cancer cell lines examined (Figure 6a ). In contrast, qRT-PCR analysis revealed that the expression of miR-99a was greatly reduced in most of the lung cancer cells (Figure 6b ). The levels of mTOR and FGFR3 were not necessarily correlated with the amount of protein or the activity status of c-Src (pY418), which reflects the potential contribution of other signaling components to human cancers (Figure 6a ). Human cancer cells contain multiple mutations in oncogenes and tumor suppressor genes. A549 has c-Src upregulation and a K-Ras mutation; Lu99 harbors a K-Ras mutation; H69 and H526 have an N-myc amplification; PC9 has an EGFR mutation; and PC10 has a c-Src upregulation as well as a PTEN mutation (Yokota and Kohno, 2004; Noro et al., 2006) . These lines of information suggest that there is an upregulation of the Src-related oncogenic pathways in these cells, which may account for the downregulation of miR-99a observed in various human cancer cells.
To examine the functional link between miR-99a and mTOR/FGFR3 in human cancers, we ectopically expressed miR-99a in lung (A549, PC10 and Lu99) cancer cells. The expression of miR-99a in A549 cells induced a significant downregulation of mTOR and FGFR3 proteins (Figure 6c ) and significantly suppressed the colony-forming activity of A549, PC10 and Lu99 cells (Figure 6d) . Conversely, knockdown of miR99a in A549 cells increased mTOR and FGFR3 expressions and colony-forming activity (Figures 6c  and e) . In addition, inactivation of miR-99a induced an anchorage-independent growth in human normal epithelial cells such as HEK293 and HaCaT (Supplementary Figure S5 ). These results suggest that miR-99a downregulation is involved in carcinogenesis and malignancy in human cells.
The importance of mTOR upregulation in tumor growth was further confirmed by observing that short hairpin RNA-mediated mTOR knockdown in A549 cells appreciably suppressed colony-forming activity (Supplementary Figure S6) . Interestingly, the effect of miR-99a expression was more evident in vivo: tumorigenesis in nude mice was potently suppressed by miR99a expression in A549 cells (Figure 6f ). These findings suggest that miR-99a is involved in regulating tumor growth of a subset of human cancer cells by targeting mTOR/FGFR3. miR-99a in human cancer tissues Finally, we verified the role of miR-99a in human cancers by determining miR-99a expression in lung primary tumors as well as in adjacent normal tissues using qRT-PCR. In most of the tumor samples examined, miR-99a was significantly downregulated (Figure 7a ). Immunohistochemical analysis of mTOR and FGFR3 expression in lung tumor specimens showed that mTOR and FGFR3 immunoreactivity was greatly increased in all of the five primary tumor regions in comparison to the adjacent normal tissues (Figure 7b ). These observations suggest that there is an inverse correlation between the expressions of miR-99a and mTOR/FGFR3 even in human cancer tissues.
miR-99a controls c-Src-mediated tumor growth C Oneyama et al
Overall, the present findings suggest that downregulation of miR-99a is induced by the activation of Srcrelated oncogenic pathways in various human cancers, and is tightly associated with the promotion of tumor growth via upregulation of mTOR/FGFR3 pathways (Figure 7c ).
Discussion
To elucidate the molecular mechanisms underlying c-Src-mediated transformation, we previously established an experimental system using Csk-deficient cells (Oneyama et al., 2008) . In this study, we used this miR-99a controls c-Src-mediated tumor growth C Oneyama et al system to study the potential role of miRNAs in c-Srcmediated tumor growth. The miRNA profiling identified seven miRNAs that were downregulated by c-Src transformation. A previous study showed that the expression of nine of 95 miRNAs that had been implicated in cancer, development and apoptosis was miR-99a controls c-Src-mediated tumor growth C Oneyama et al affected by v-Src transformation (Li et al., 2009 ). More recently, it was shown that 29 miRNAs were differentially expressed during transformation of MCF10A-ERSrc cells (Iliopoulos et al., 2010) . However, the miRNA species identified in the previous studies, such as miR-126, -218, -224, -21 or -181b-1 relevant to Src signaling and cancer, are not necessarily consistent with those identified in this study. Although the actual reasons are currently unclear, this inconsistency might be due to the difference in the pathways activated by v-Src and c-Src, or related to the cellular context. Because upregulation of c-Src protein and/or activity, rather than gain-offunction mutations in the c-src gene, widely contributes to the progression of human cancers, c-Src-transformed cells were used to identify miRNAs crucial for regulating human cancers. Of the miRNAs downregulated by c-Src activation, we first focused on miR-99a, because recent reports suggested a potential tumor suppressor function of this miRNA in various human cancers (Yamada et al., 2008; Doghman et al., 2010; Gao et al., 2010) . We showed that it targets mTOR and FGFR3, both of which have been implicated in human cancers (Eswarakumar et al., 2005; Guertin and Sabatini, 2007) . A more recent study also showed that miR-99a can target the IGF-IR-mTORraptor pathway in a specific subset of human cancers (Doghman et al., 2010) , suggesting a role for miR-99a in regulating the oncogenic function of mTOR. However, the functional link between miR-99a and cancer progression is unclear, and the mechanisms underlying the downregulation of miR-99a in cancers remains to be addressed. This study provides the first firm evidence for tumor suppressive role of miR-99a and suggests that the expression of miR-99a is regulated via the Src-related oncogenic pathways involving EGFR, c-Src, K/H-Ras and MEK/ERK. In addition, the first evidence that perturbation of mTOR protein levels can directly contribute to controlling tumor growth is presented. As the Src-related oncogenic pathway is frequently activated in various human cancers, the functional analysis of the miR-99a-mTOR/FGFR3 axis driven by the EGFR/Src/Ras/MAPK pathway represents a great leap forward in our understanding of cancer etiology. Indeed, various human cancer cells, which harbor deregulation of c-Src, EGFR, K-Ras or N-myc, were shown to exhibit downregulation of miR-99a and upregulation of mTOR/FGFR3. The inhibition of mTOR function or introduction of miR-99a successfully suppressed tumor growth in certain types of human cancer cells. Furthermore, the existence of an inverse correlation between miR-99a and mTOR/FGFR3 in primary human cancer tissues was shown. Considering the crucial role of mTOR in various cancers, these observations support our proposal that the Src pathway-miR-99a-mTOR/FGFR3 axis is important in controlling tumor growth in a wide array of human cancers.
The substantial downregulation of miR-99a in human lung tumors suggests a crucial role for miR-99a as a regulator of these cancers. The miR-99a gene is located on chromosome 21q21.1, which was identified as a minimal region where loss of heterozygosity frequently occurs in cases of human lung cancer (Yamada et al., 2008) . The qRT-PCR analysis of miR-99a expression levels in a panel of lung cancer cell lines revealed a substantial reduction of miR-99a expression to less than one-tenth that of normal lung expression. To examine the possibility that these cell lines carry a homozygous deletion at 21q21.1, loss of heterozygosity analysis of A549 and PC10 cells was performed by genomic PCR, which confirmed that the 21q21.1 region is intact in these cells (data not shown). This observation suggests that activation of the Src/Ras-related oncogenic pathway, for example, K-Ras mutation, more widely contributes to the downregulation of miR-99a in cancer cells. However, downstream mechanisms that lead to changes in miR-99a gene expression remain unclear. Further extensive analysis will be necessary to elucidate the precise mechanism of miR-99a downregulation.
We also observed that ectopic expression of miR-99a suppressed anchorage-independent growth and tumorigenesis of c-Src-transformed cells, but it only moderately affected cell morphology. This could be attributed to the specific roles of mTOR and FGFR3 in regulating tumor growth and survival, respectively. On the basis of these findings, we propose a hypothetical model for the function of the miR-99a-mTOR/FGFR3 axis in tumor growth (Figure 7c ). Downregulation of miR-99a caused by the activation of Src-related pathways results in the upregulation of mTOR and FGFR3, which in turn activate protein synthesis and the PI3K pathway, respectively, and promote tumor growth and survival. Earlier studies suggested that Src activity plays a critical role in the deregulation of mTOR signaling pathways, but the functional link between Src and mTOR was unclear (Penuel and Martin, 1999; Vojtechova et al., 2008) . It was also seen that mTOR is often overexpressed and activated in a wide variety of human cancers (Hay, 2005; Sabatini, 2006; Nozawa et al., 2007) ; however, the underlying mechanisms remained unknown. This model for miR-99a function would provide a missing link between Src, mTOR and cancer progression.
The potential role of miRNA in mTOR regulation has previously been shown in studies of miR-100, an miRNA that contains the same seed sequences as miR99a. It has been reported that miR-100 is downregulated in human cytomegalovirus infection and that re-expression of miR-100 reduces mTOR protein levels (Wang et al., 2008) . In addition, miR-100 is downregulated in clear cell ovarian cancer (Nagaraja et al., 2010) and childhood adrenocortical tumors (Doghman et al., 2010) , and the overexpression of miR-100 inhibits mTOR signaling and enhances sensitivity to a mTOR inhibitor RAD001 (Nagaraja et al., 2010) . More recently, miR-199a-3p was also shown to be downregulated and target mTOR in hepatocarcinoma cells (Fornari et al., 2010) . These features of miR-100 and miR-199a-3p are quite similar to those of miR-99a, suggesting that mTOR expression might be regulated redundantly by these closely related miRNAs. However, downregulation of miR-100 and miR-199a-3p in c-SrcmiR-99a controls c-Src-mediated tumor growth C Oneyama et al transformed cells could not be detected (data not shown); this indicates that the expression of miR-100 and miR-199a-3p may be regulated through a pathway independent of the Src-related pathway or in different cellular contexts. Nonetheless, these findings strongly highlight a critical role of miRNA-mediated regulation of mTOR signaling in controlling tumor growth in various human cancers.
In conclusion, we have shown a crucial role for the Src-miR-99a-mTOR/FGFR3 axis in controlling tumor growth. Our study provides insights into the function of this new signaling axis, and offers new opportunities for therapeutic intervention in a wide array of human cancers.
Materials and methods
Pre-miR-99a and anti-miR-99a transfection miR-99a precursor (PM10719), antisense miR-99a (AM11465) and control miR (AM17110) were purchased from Applied Biosystems (Foster City, CA, USA). The day before transfection, 2.5 Â 10 5 cells were seeded onto six-well plates. Different concentrations of precursors (0.3-30 nM) and inhibitors (3-30 nM), as well as the negative control, were transfected using Lipofectamine RNAiMAX in 16 ml per six-well plates according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Using this approach, 90% of cells were transfected as judged by comparison to FAM-labeled controls (AM17121; Applied Biosystems).
Soft-Agar colony formation assay
Single-cell suspensions of 2 Â 10 4 cells were plated in six-well culture dishes in 1.5 ml of Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 0.36% agar on a layer of 2.5 ml of the same medium containing 0.7% agar. Colonies were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma, St Louis, MO, USA) 7-14 days after plating, and micrographs of the stained colonies were used to count the numbers of colonies.
Tumorigenesis assays
Immunodeficient mice (BALB/c AJc1-nu/nu; Japan CLEA, Tokyo, Japan) were injected subcutaneously with 1 Â 10 6 cells suspended in 200 ml of serum-free Dulbecco's modified Eagle's medium at one location. Tumors were monitored every 2 or 3 days and the tumor volume was estimated using the following formula: 0.5 Â L Â W 2 . At least three mice were used in each experiment. The mice used for this study were handled in strict adherence with local governmental and institutional animal care regulations.
Immunohistochemistry
Histological specimens were fixed in 10% formalin and routinely processed for paraffin embedding. Histological sections 4-mm thick were stained with hematoxylin and eosin and reviewed by two pathologists (JI and EM) to define the cancerous and corresponding normal tissues. An immunoperoxidase procedure was performed on the paraffin-embedded sections as described below. After antigen retrieval using a Pascal pressurized heating chamber (Dako A/S, Glostrup, Denmark), the sections were incubated with anti-mTOR or anti-FGFR3 antibody that was diluted at 1:50. Cells were then treated with a ChemMate EnVision kit (Dako). Diaminobenzidine (Dako) was used as a chromogen. As a negative control, staining was carried out in the absence of primary antibody. Stained sections were evaluated independently by two pathologists (JI and EM).
